This research delves into the implications of the RNA binding motif, single stranded interacting protein 2 (RBMS2)—a gene associated with tumor-suppressing functions—in the context of kidney renal clear cell carcinoma (ccRCC). Through meticulous exploration of online databases, we have identified a negative association between RBMS2 expression and adverse clinico-pathological features, such as advanced TNM stage. Furthermore, our findings indicate that RBMS2 acts as a prognostic predictor for clinical outcomes in ccRCC, evidenced by both univariate and multivariate analyses. Cellular assays have corroborated these findings, revealing that an overexpression of RBMS2 curtails ccRCC cell proliferation and migration. Additionally, our research has unearthed links between RBMS2 and immune infiltration within the ccRCC tumor microenvironment. Collectively, our results underscore the tumor-inhibiting role of RBMS2 in ccRCC and spotlight its potential as a prognostic marker and therapeutic intervention target.

这项研究深入探讨了 RNA 结合基序、单链相互作用蛋白 2 (RBMS2)（一种与肿瘤抑制功能相关的基因）在肾透明细胞癌 (ccRCC) 中的影响。通过对在线数据库的细致探索，我们发现 RBMS2 表达与不良临床病理特征（例如晚期 TNM 分期）之间存在负相关。此外，我们的研究结果表明，单变量和多变量分析都证明了 RBMS2 可作为 ccRCC 临床结果的预后预测因子。细胞检测证实了这些发现，表明 RBMS2 的过度表达会抑制 ccRCC 细胞的增殖和迁移。此外，我们的研究还发现了 RBMS2 与 ccRCC 肿瘤微环境中的免疫浸润之间的联系。总的来说，我们的结果强调了 RBMS2 在 ccRCC 中的肿瘤抑制作用，并强调了其作为预后标志物和治疗干预目标的潜力。